Publications by authors named "Albert J Oosting"
Introduction And Objectives: Tralokinumab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). Although safety and efficacy have been shown in phase-III clinical trials, daily practice data are needed. Therefore, the aim of this study was to evaluate 28-week safety and effectiveness, serum proteins and total IgE levels in adult AD patients treated with tralokinumab in daily practice.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the long-term effectiveness and safety of dupilumab, a treatment for atopic dermatitis (AD), in a diverse group of patients over a period of up to 5 years.
- Conducted in the Netherlands using the BioDay registry, the research includes 1,286 patients of different age groups receiving dupilumab between 2017 and 2022, with outcomes evaluated using various clinical measures.
- Results show that a majority of patients maintained controlled AD symptoms, with high levels of treatment effectiveness observed over time, and factors for treatment discontinuation were also assessed.
Article Synopsis
- A study evaluated the effectiveness and safety of dupilumab for treating moderate-to-severe atopic dermatitis (AD) over a long-term period of up to 5 years, emphasizing patient-reported outcomes.
- Data from 1223 patients (1108 adults and 115 children) showed improved quality of life measures and work impairment in both groups after at least one year of treatment.
- Despite the treatment's favorable safety profile, including a 66.8% reporting rate of adverse events (most commonly conjunctivitis), there were significant amounts of missing data in reported outcomes, particularly in children.
Article Synopsis
- The study examines patient-centred dosing of dupilumab for atopic dermatitis (AD), focusing on its effectiveness and cost savings in daily practice.
- A total of 595 adult patients were assessed, with 401 managing to successfully taper their dupilumab treatment after controlling their eczema symptoms for over a year.
- Successful tapering was achieved in 83.3% of cases, suggesting that reducing medication frequency is both effective for patient health and economically beneficial, with estimated savings of nearly €4 million.
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
JAMA Dermatol
September 2022
Article Synopsis
- Long-term data on the survival of dupilumab in patients with atopic dermatitis (AD) is limited, and there is a need to understand what factors influence its effectiveness over time.
- The study analyzed data from 715 adult patients in the Netherlands, showing that dupilumab had drug survival rates of 90.3%, 85.9%, and 78.6% at 1, 2, and 3 years, respectively.
- Factors linked to shorter drug survival included the use of immunosuppressants and being a nonresponder at 4 weeks, as well as age over 65 and severe forms of AD, indicating specific characteristics that could predict treatment outcomes.
Background: The incidence of keratinocyte carcinomas is high and rapidly growing. Approximately 80% of keratinocyte carcinomas consist of basal cell carcinomas (BCC) with 50% of these being considered as low-risk tumors. Nevertheless, 83% of the low-risk BCC patients were found to receive more follow-up care than recommended according to the Dutch BCC guideline, which is one visit post-treatment for this group.
View Article and Find Full Text PDFDupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
J Am Acad Dermatol
April 2021
Background: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.
Objective: To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.
Methods: Patients treated with dupilumab and participating in the Dutch BioDay registry were included.
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.
Allergy
September 2020
Background: Encasing bedding in impermeable covers reduces exposure to house-dust mites, but the clinical benefit of this intervention as part of mite-avoidance measures for patients with allergic rhinitis is not known. We performed a multicenter, randomized, placebo-controlled trial of one year of use of impermeable bedding covers in the bedrooms of patients with rhinitis who were sensitized to house-dust mites to determine the effects on the signs and symptoms of disease.
Methods: Three participating university medical centers enrolled 279 patients with allergic rhinitis who were randomly assigned to receive impermeable or non-impermeable (control) covers for their mattress, pillow, and duvet or blanket.